These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 27402434)

  • 1. The Australasian Psoriasis Collaboration view on methotrexate for psoriasis in the Australasian setting.
    Rademaker M; Gupta M; Andrews M; Armour K; Baker C; Foley P; Gebauer K; George J; Rubel D; Sullivan J
    Australas J Dermatol; 2017 Aug; 58(3):166-170. PubMed ID: 27402434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methotrexate in psoriasis: a systematic review of treatment modalities, incidence, risk factors and monitoring of liver toxicity.
    Montaudié H; Sbidian E; Paul C; Maza A; Gallini A; Aractingi S; Aubin F; Bachelez H; Cribier B; Joly P; Jullien D; Le Maître M; Misery L; Richard MA; Ortonne JP
    J Eur Acad Dermatol Venereol; 2011 May; 25 Suppl 2():12-8. PubMed ID: 21388454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short-term methotrexate therapy in psoriasis: a study of 197 patients.
    Kumar B; Saraswat A; Kaur I
    Int J Dermatol; 2002 Jul; 41(7):444-8. PubMed ID: 12121564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatotoxic potentials of methotrexate: Understanding the possible toxicological molecular mechanisms.
    Ezhilarasan D
    Toxicology; 2021 Jun; 458():152840. PubMed ID: 34175381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of methotrexate (0.3 mg/kg/week) versus a combination of methotrexate (0.15 mg/kg/week) with cyclosporine (2.5 mg/kg/day) in chronic plaque psoriasis: A randomised non-blinded controlled trial.
    Singh SK; Singnarpi SR
    Indian J Dermatol Venereol Leprol; 2021; 87(2):214-222. PubMed ID: 33769732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and safety of Methotrexate in psoriasis: an eight-year experience with 218 patients.
    Cabello Zurita C; Grau Pérez M; Hernández Fernández CP; González Quesada A; Valerón Almazán P; Vilar Alejo J; Carretero Hernández G
    J Dermatolog Treat; 2017 Aug; 28(5):401-405. PubMed ID: 28001499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A retrospective review of methotrexate-induced hepatotoxicity among patients with psoriasis in a tertiary dermatology center in Malaysia.
    Ng LC; Lee YY; Lee CK; Wong SM
    Int J Dermatol; 2013 Jan; 52(1):102-5. PubMed ID: 23278617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of methotrexate in patients with psoriasis.
    Kuhn A; Ruland V; Patsinakidis N; Luger TA
    Clin Exp Rheumatol; 2010; 28(5 Suppl 61):S138-44. PubMed ID: 21044448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Methotrexate].
    Beylot-Barry M; Le Maitre M
    Ann Dermatol Venereol; 2011 Dec; 138(12):833-5. PubMed ID: 22137621
    [No Abstract]   [Full Text] [Related]  

  • 10. Concurrent use of methotrexate and acitretin revisited.
    Lowenthal KE; Horn PJ; Kalb RE
    J Dermatolog Treat; 2008; 19(1):22-6. PubMed ID: 18273721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic methotrexate therapy for psoriasis: past, present and future.
    Dogra S; Mahajan R
    Clin Exp Dermatol; 2013 Aug; 38(6):573-88. PubMed ID: 23837932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Folic acid supplementation during treatment of psoriasis with methotrexate: a randomized, double-blind, placebo-controlled trial.
    Salim A; Tan E; Ilchyshyn A; Berth-Jones J
    Br J Dermatol; 2006 Jun; 154(6):1169-74. PubMed ID: 16704650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of mycophenolate mofetil vs. methotrexate for the treatment of chronic plaque psoriasis.
    Akhyani M; Chams-Davatchi C; Hemami MR; Fateh S
    J Eur Acad Dermatol Venereol; 2010 Dec; 24(12):1447-51. PubMed ID: 20384673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Algorithm to select optimal systemic anti-psoriatic drugs in relation with patients' Psoriasis Area and Severity Index score for plaque psoriasis.
    Bae SH; Yun SJ; Lee JB; Kim SJ; Won YH; Lee SC
    J Dermatol; 2016 Jun; 43(6):643-9. PubMed ID: 26598783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liver biopsies from psoriatics related to methotrexate therapy. 2. Findings before and after methotexate therapy in 88 patients. A blind study.
    Nyfors A; Poulsen H
    Acta Pathol Microbiol Scand A; 1976 May; 84(3):262-70. PubMed ID: 1274591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The value of dynamic hepatic scintigraphy and serum aminoterminal propeptide of type III procollagen for early detection of methotrexate-induced hepatic damage in psoriasis patients.
    vanDooren-Greebe RJ; Kuijpers AL; Buijs WC; Kniest PH; Corstens FH; Nagengast FM; de Boo T; Willems JL; Duller P; van de Kerkhof PC
    Br J Dermatol; 1996 Mar; 134(3):481-7. PubMed ID: 8731673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic methotrexate for the treatment of psoriasis.
    Yélamos O; Puig L
    Expert Rev Clin Immunol; 2015 May; 11(5):553-63. PubMed ID: 25779551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of non-alcoholic steatohepatitis in methotrexate-induced liver injury.
    Langman G; Hall PM; Todd G
    J Gastroenterol Hepatol; 2001 Dec; 16(12):1395-401. PubMed ID: 11851839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination therapy of biologics with traditional agents in psoriasis.
    Guenther LC
    Skin Therapy Lett; 2011 Jun; 16(6):1-3. PubMed ID: 21833461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vitamin D and systemic therapy.
    van de Kerkhof P
    Cutis; 2002 Nov; 70(5 Suppl):16-20. PubMed ID: 12467335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.